| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Paulina Gonzalez-Latapi, Suvorit Subhas Bhowmick, Gerard Saranza, Susan H Fo. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. CNS drugs. vol 34. issue 10. 2021-10-20. PMID:32785890. |
the largest area of development in non-dopaminergic targets has been for motor complications of dopamine replacement therapy (motor fluctuations and dyskinesia). |
2021-10-20 |
2023-08-13 |
Not clear |
| Daniele Urso, K Ray Chaudhuri, Mubasher A Qamar, Peter Jenne. Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies. CNS drugs. vol 34. issue 11. 2021-10-20. PMID:33146817. |
it is widely accepted that levodopa needs to be administered using formulations that result in good and consistent bioavailability and the physiologically relevant and continuous formation of dopamine in the brain to maximise its efficacy while avoiding and reversing 'wearing off' and dyskinesia. |
2021-10-20 |
2023-08-13 |
Not clear |
| Lauren Malave, Dustin R Zuelke, Santiago Uribe-Cano, Lev Starikov, Heike Rebholz, Eitan Friedman, Chuan Qin, Qin Li, Erwan Bezard, Andreas H Kottman. Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia. Communications biology. vol 4. issue 1. 2021-10-09. PMID:34552196. |
l-dopa induced dyskinesia (lid) is a debilitating side effect of dopamine replacement therapy for parkinson's disease. |
2021-10-09 |
2023-08-13 |
mouse |
| Laura Andreoli, Morteza Abbaszadeh, Xiao Cao, Maria Angela Cenc. Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. Neurobiology of disease. vol 157. 2021-10-01. PMID:34153463. |
l-dopa-induced dyskinesia (lid) is a significant complication of dopamine replacement therapy in parkinson's disease (pd), and the specific role of different dopamine receptors in this disorder is poorly understood. |
2021-10-01 |
2023-08-13 |
mouse |
| P A Caro Aponte, C A Otálora, J C Guzmán, L F Turner, J P Alcázar, E L Mayorg. Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia. Neurologia (Barcelona, Spain). vol 36. issue 3. 2021-09-08. PMID:29525397. |
although the pathogenic mechanism of l-dopa-induced dyskinesia is unclear, the condition has been associated with alterations in dopamine receptors, among which d2 receptors (d2r) have received little attention. |
2021-09-08 |
2023-08-13 |
rat |
| Hassaan Gomaa, Yassir Mahgoub, Andrew Franci. Covert Dyskinesia With Aripiprazole: Tip of the Iceberg? A Case Report and Literature Review. Journal of clinical psychopharmacology. vol 41. issue 1. 2021-09-07. PMID:33347026. |
covert dyskinesia (cd), a form of td, occurs after the discontinuation of antipsychotics, and it differs from other withdrawal emergent dyskinesia by its persistence for more than 8 to 12 weeks after discontinuation of dopamine receptor-blocking agents. |
2021-09-07 |
2023-08-13 |
Not clear |
| Kathryn Lanza, Ashley Centner, Michael Coyle, Isabella Del Priore, Fredric P Manfredsson, Christopher Bisho. Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia. Experimental neurology. vol 336. 2021-08-30. PMID:33249031. |
genetic suppression of the dopamine d3 receptor in striatal d1 cells reduces the development of l-dopa-induced dyskinesia. |
2021-08-30 |
2023-08-13 |
rat |
| Melina P Bordone, Ana Damianich, M Alejandra Bernardi, Tomas Eidelman, Sara Sanz-Blasco, Oscar S Gershanik, M Elena Avale, Juan E Ferrari. Fyn knockdown prevents levodopa-induced dyskinesia in a mouse model of Parkinson's disease. eNeuro. 2021-08-27. PMID:34099487. |
dopamine replacement by levodopa is the most widely used therapy for parkinson's disease (pd), however patients often develop side effects, known as levodopa-induced dyskinesia (lid), that usually need therapeutic intervention. |
2021-08-27 |
2023-08-13 |
mouse |
| Elena Contaldi, Luca Magistrelli, Anna V Milner, Marco Cosentino, Franca Marino, Cristoforo Com. Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study. Neural regeneration research. vol 16. issue 12. 2021-08-26. PMID:33907036. |
growing evidence has highlighted that angiotensin-converting enzyme (ace)-inhibitors (acei)/at1 receptor blockers (arbs) may influence the complex interplay between dopamine and the renin-angiotensin system in the nigrostriatal pathway, thus affecting the development of levodopa-induced dyskinesia in parkinson's disease (pd). |
2021-08-26 |
2023-08-13 |
Not clear |
| Shin-Ichiro Kubo, Ken Nakamura, Yoshimasa Tada, Nobuyuki Kashio, Shinya Yamashit. What can we learn from the effect of trihexyphenidyl on motor fluctuations during continuous levodopa-carbidopa intestinal gel infusion (LCIG)? - First documented case. Clinical parkinsonism & related disorders. vol 3. 2021-07-29. PMID:34316650. |
lcig significantly reduces "off" time and increases "on" time without dyskinesia in comparison to standard oral levodopa through consistent plasma concentration of levodopa to restore brain dopamine in a more physiological manner. |
2021-07-29 |
2023-08-13 |
Not clear |
| Yong Wang, Lu Yao, Shasha Gao, Gejuan Zhang, Qiongchi Zhang, Wanyuan Liu, Yingqiong Zhou, Yina Sun, Jie Feng, Jian Li. Inhibition of striatal dopamine D Brain research. vol 1754. 2021-07-22. PMID:33422541. |
inhibition of striatal dopamine d levodopa-induced dyskinesia (lid) is experienced by most patients of parkinson's disease (pd) upon the long-term use of the dopamine precursor levodopa. |
2021-07-22 |
2023-08-13 |
Not clear |
| Yousef Tizabi, Bruk Getachew, Michael Aschne. Novel Pharmacotherapies in Parkinson's Disease. Neurotoxicity research. vol 39. issue 4. 2021-07-13. PMID:34003454. |
the most common treatment for pd is focused on dopamine (da) replacement (e.g., levodopa = l-dopa), which unfortunately losses its efficacy over months or years and can induce severe dyskinesia. |
2021-07-13 |
2023-08-13 |
Not clear |
| Feras Altwal, Connor Moon, Anthony R West, Heinz Steine. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells. vol 9. issue 10. 2021-07-02. PMID:33050305. |
such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from serotonin terminals. |
2021-07-02 |
2023-08-13 |
rat |
| Nicole E Chambers, Michael Coyle, Jordan Sergio, Kathryn Lanza, Carolyn Saito, Brent Topping, Stewart D Clark, Christopher Bisho. Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. The European journal of neuroscience. vol 53. issue 8. 2021-06-30. PMID:33426708. |
the abnormal involuntary movements scale measured l-dopa and dopamine d1- and d2-receptor agonist-induced dyskinesia. |
2021-06-30 |
2023-08-13 |
rat |
| Ivo E Sampaio-Dias, Ana Reis-Mendes, Vera Marisa Costa, Xerardo García-Mera, José Brea, María Isabel Loza, Beatriz L Pires-Lima, Cristina Alcoholado, Manuel Algarra, José E Rodríguez-Borge. Discovery of New Potent Positive Allosteric Modulators of Dopamine D Journal of medicinal chemistry. vol 64. issue 9. 2021-06-14. PMID:33861612. |
discovery of new potent positive allosteric modulators of dopamine d the control of parkinson's disease (pd) is challenged by the motor and non-motor fluctuations as well as dyskinesias associated with levodopa long-term therapy. |
2021-06-14 |
2023-08-13 |
Not clear |
| Samuel Booth, Abdullah Ramadan, Dali Zhang, Lingling Lu, Gilbert Kirouac, Michael F Jackson, Chris Anderson, Ji Hyun K. The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia. Movement disorders : official journal of the Movement Disorder Society. vol 36. issue 4. 2021-05-19. PMID:33135810. |
the vasomotor response to dopamine is altered in the rat model of l-dopa-induced dyskinesia. |
2021-05-19 |
2023-08-13 |
rat |
| Xi Chen, Yuanyuan Wang, Haifeng Wu, Cheng Cheng, Weidong L. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 41. issue 8. 2021-05-14. PMID:32185625. |
besides l-dopa, dopamine agonists are able to induce dyskinesia as well. |
2021-05-14 |
2023-08-13 |
mouse |
| Sini K Koski, Sakari Leino, Pertti Panula, Saara Rannanpää, Outi Salmine. Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease. Neuroscience letters. vol 729. 2021-05-14. PMID:32224226. |
genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of parkinson's disease. |
2021-05-14 |
2023-08-13 |
mouse |
| Young-Kyoung Ryu, Hye-Yeon Park, Jun Go, In-Bok Lee, Young-Keun Choi, Chul-Ho Lee, Kyoung-Shim Ki. β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease. Molecular medicine reports. vol 23. issue 3. 2021-05-04. PMID:33495840. |
the dopamine precursor 3,4‑dihydroxyphenyl‑ l‑alanine (l‑dopa) is the most widely used symptomatic treatment for parkinson's disease (pd); however, its prolonged use is associated with l‑dopa‑induced dyskinesia in more than half of patients after 10 years of treatment. |
2021-05-04 |
2023-08-13 |
mouse |
| Louise-Laure Marian. [Continuous and advanced treatment strategies in the old to very old parkinsonian population]. Geriatrie et psychologie neuropsychiatrie du vieillissement. vol 18. issue 2. 2021-04-27. PMID:32338612. |
on the other hand, patients presenting with advanced pd, in which fluctuations and dyskinesia induced by dopamine replacement therapy and dopa-resistant axial symptoms impede patient's daily life. |
2021-04-27 |
2023-08-13 |
Not clear |